LWP
ALNY icon

Lumature Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lumature Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40
Closed -$7K – 412
2022
Q1 		$7K Sell
40
-60
-60% -$9.14K ﹤0.01% 357
2021
Q4 		$17K Sell
100
-50
-33% -$9.29K 0.01% 301
2021
Q3 		$28K Sell
150
-61
-29% -$11.4K 0.01% 263
2021
Q2 		$36K Buy
211
+10
+5% +$1.47K 0.01% 246
2021
Q1 		$28K Sell
201
-2,326
-92% -$350K 0.01% 250
2020
Q4 		$328K Buy
+2,527
New +$337K 0.31% 96

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lumature Wealth Partners's ALNY Position: Q2 2022 in Review

Lumature Wealth Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 40 shares — an estimated $7K sold.

Lumature Wealth Partners first reported a position in ALNY in Q4 2020 and held it in 6 quarters. The position peaked at $328K in Q4 2020. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Lumature Wealth Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Lumature Wealth Partners sold 40 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $7K.
  • Lumature Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Lumature Wealth Partners's Alnylam Pharmaceuticals position peaked at $328K in Q4 2020.
  • 423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Lumature Wealth Partners's 13F filing for Q2 2022, filed 10 Aug 2022.